Abstract
Background: Renin-angiotensin system (RAS) and its main product Angiotensin II (AngII) are in the focus of the pharmacological industry mainly because of hypertension treatment. Up-regulated RAS is generally associated with cardiovascular diseases and consequent organs injuries. The classic inhibition of RAS is based on the blocking of the type 1 AngII receptors and inhibition of ACE. The concept of the circulating and tissue RAS opens new challenges for the drug targeting. In spite of a big effort invested, in some cases a traditional RAS manipulation is struggling with unwanted side effects and/or resistance to treatment.
Objective: To improve the efficiency of the classic RAS inhibitors specific complications issuing from feed-back circuits inside the RAS have to be elucidated. Moreover, new peptidases identified in the AngII biosynthesis and Angiotensin 1-7/MAS pathways with opposing effects to AngII are tested for the clinical use. The aim of this review is also to bring attention to new tools in RAS manipulation based on the RNA interference (RNAi). RNAi employs small non-coding nucleic acids that interfere with the mRNA translation. The usefulness of this approach has been demonstrated in the treatment of oncological diseases and progress was also made in the field of the cardiovascular medicine.
Conclusion: We suppose that in the near future, in addition to traditional pharmacological tools, RNAi will contribute to the control of RAS and AngII production. RNAi may also be of importance in the manipulation of tissue RAS that is not easily accessible by the traditional chemical substances.
Keywords: siRNA, miRNA, silencing, RNAi, angiotensinogen, renin, ACE, Alamandine.
Current Medicinal Chemistry
Title:Angiotensin II in the Human Physiology: Novel Ways for Synthetic Compounds Utilization
Volume: 23 Issue: 42
Author(s): Iveta Herichová
Affiliation:
Keywords: siRNA, miRNA, silencing, RNAi, angiotensinogen, renin, ACE, Alamandine.
Abstract: Background: Renin-angiotensin system (RAS) and its main product Angiotensin II (AngII) are in the focus of the pharmacological industry mainly because of hypertension treatment. Up-regulated RAS is generally associated with cardiovascular diseases and consequent organs injuries. The classic inhibition of RAS is based on the blocking of the type 1 AngII receptors and inhibition of ACE. The concept of the circulating and tissue RAS opens new challenges for the drug targeting. In spite of a big effort invested, in some cases a traditional RAS manipulation is struggling with unwanted side effects and/or resistance to treatment.
Objective: To improve the efficiency of the classic RAS inhibitors specific complications issuing from feed-back circuits inside the RAS have to be elucidated. Moreover, new peptidases identified in the AngII biosynthesis and Angiotensin 1-7/MAS pathways with opposing effects to AngII are tested for the clinical use. The aim of this review is also to bring attention to new tools in RAS manipulation based on the RNA interference (RNAi). RNAi employs small non-coding nucleic acids that interfere with the mRNA translation. The usefulness of this approach has been demonstrated in the treatment of oncological diseases and progress was also made in the field of the cardiovascular medicine.
Conclusion: We suppose that in the near future, in addition to traditional pharmacological tools, RNAi will contribute to the control of RAS and AngII production. RNAi may also be of importance in the manipulation of tissue RAS that is not easily accessible by the traditional chemical substances.
Export Options
About this article
Cite this article as:
Herichová Iveta, Angiotensin II in the Human Physiology: Novel Ways for Synthetic Compounds Utilization, Current Medicinal Chemistry 2016; 23 (42) . https://dx.doi.org/10.2174/0929867323666161014144552
DOI https://dx.doi.org/10.2174/0929867323666161014144552 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Evolving Concepts Concerning Cardiac β-Adrenoceptor Function in Heart Failure
Current Pharmaceutical Design A Perspective on the Current Strategies for the Treatment of Obesity
Current Drug Targets - CNS & Neurological Disorders Curcumin Reverts the Protein Differential Expression in the Liver of the Diabetic Obese db/db Mice
Current Proteomics MR Imaging of Pancreatic Islets: Tracking Isolation, Transplantation and Function
Current Pharmaceutical Design Combining Diffusion-Weighted Imaging Patterns with ABCD2 Score Predicts Stroke Risk after Transient Ischemic Attack
Current Neurovascular Research Speciation of Metal Complexes of Medicinal Interest: Relationship between Solution Equilibria and Pharmaceutical Properties
Current Medicinal Chemistry Oxidized Polysaccharides as Green and Sustainable Biomaterials
Current Organic Chemistry Central Nervous System Manifestations in Systemic Lupus Erythematosus
Current Rheumatology Reviews Regulation of Insulin Synthesis and Secretion and Pancreatic Beta-Cell Dysfunction in Diabetes
Current Diabetes Reviews Use of Continuous Glucose Monitoring in Patients with Type 1 Diabetes
Current Diabetes Reviews p53: Fighting Cancer
Current Cancer Drug Targets Is Whole-Body Thermoregulatory Function Impaired in Type 1 Diabetes Mellitus?
Current Diabetes Reviews Gut Microbiota in Vascular Disease: Therapeutic Target?
Current Vascular Pharmacology Cardiac and Metabolic Consequences of Aerobic Exercise Training in Experimental Diabetes
Current Diabetes Reviews Determinants of Left Ventricular Hypertrophy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Editorial [Hot topic: Sepsis Pathogenesis: How Many Pieces are There in the Puzzle? (Guest Editor: Luciano Cesar Pontes Azevedo)]
Endocrine, Metabolic & Immune Disorders - Drug Targets Editorial [Hot Topic: Drugs Targeting Atherosclerosis: Current and Emerging Approaches (Executive Editors: Vangelis G. Manolopoulos and Anna Tavridou)]
Current Pharmaceutical Design Angiogenic Properties of Primary Cells Intended at Bone Regeneration: A Comparison to Differentiated Cells Using the CAM Assay
Current Angiogenesis (Discontinued) Cancer Targeted Therapy Strategy: The Pathologist’s Perspectives
Current Cancer Drug Targets Recent Contributions of Elastin-Like Recombinamers to Biomedicine and Nanotechnology
Current Topics in Medicinal Chemistry